WO2023126970A1 - Films oraux de médicaments anti-inflammatoires non stéroïdiens - Google Patents

Films oraux de médicaments anti-inflammatoires non stéroïdiens Download PDF

Info

Publication number
WO2023126970A1
WO2023126970A1 PCT/IN2022/051137 IN2022051137W WO2023126970A1 WO 2023126970 A1 WO2023126970 A1 WO 2023126970A1 IN 2022051137 W IN2022051137 W IN 2022051137W WO 2023126970 A1 WO2023126970 A1 WO 2023126970A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically acceptable
film
oral
present
oral film
Prior art date
Application number
PCT/IN2022/051137
Other languages
English (en)
Inventor
Siva Ramakrishna Velaga
Siva Ramakrishna RAYALA
Srikant PIMPLE
Narendra Kumar Kavuri
Original Assignee
Laurus Labs Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laurus Labs Limited filed Critical Laurus Labs Limited
Publication of WO2023126970A1 publication Critical patent/WO2023126970A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Definitions

  • the present invention relates to new oral dosage forms of Non-steroidal anti-inflammatory drugs (NSAIDs) and its pharmaceutically acceptable salts thereof, for veterinary use, such as for oral administration to animals. More specifically the present invention relates to oral film compositions comprising non-steroidal anti-inflammatory drugs (NSAIDs) and its pharmaceutically acceptable salts thereof and method of administering the same to the oral cavity of animals for analgesic, anti-inflammatory or anti-rheumatic activity.
  • NSAIDs non-steroidal anti-inflammatory drugs
  • NSAIDs non-steroidal anti-inflammatory drugs
  • Ibuprofen Ibuprofen
  • Naproxen Deracoxib
  • Etodolac Firocoxib
  • Carprofen Grapiprant
  • Ketoprofen Flunixin
  • Grapiprant Ketoprofen
  • Meloxicam Robenacoxib
  • Diclofenac sodium and combinations thereof.
  • COX-1 The constitutive cyclooxygenase, COX-1, synthesizes prostaglandins necessary for normal gastrointestinal and renal function.
  • the inducible cyclooxygenase COX-2 generates prostaglandins involved in pain and inflammation. Inhibition of COX-1 is thought to be associated with gastrointestinal and renal toxicity while inhibition of COX-2 provides anti-inflammatory activity.
  • Carprofen was approved in USA as tablet (25, 75, and 100 mg) dosage form in October 1996 to Zoetis (a Pfizer subsidiary) for use in Dogs under the brand name RIMADYL® for the relief of pain and inflammation associated with osteoarthritis and for the control of postoperative pain associated with soft tissue and orthopedic surgeries in dogs.
  • Other approved dosage forms include Chewable tablets, Capsules and Injections.
  • Deracoxib was approved in USA under the brand name DERAMAXX® as 12 mg, 25 mg, 50 mg, 75 mg, and 100 mg chewable tablets.
  • Etodolac was approved in USA under the brand name ETOGESIC® as 150 or 300 mg tablet dosage form.
  • Firocoxib was approved in USA under the brand name PREVICOX® as 57mg and 227mg tablets, EQUIOXX® as oral paste for administering in the oral cavity of Horses and also as injection.
  • Grapiprant was approved in USA under the brand name GALLIPRANT® as 20 mg, 60 mg, or 100 mg tablets.
  • Ketoprofen was approved in USA under the brand name KETOFEN® as lOOmg/ml Injection for treating pain in Horses and Cattle.
  • Robenacoxib was approved in USA under the brand name ONSIOR® as 10, 20, or 40 mg tablet for animal administration.
  • Meloxicam was approved in USA as oral suspension, Injection, oral spray dosage form for animal administration.
  • U.S. Patent No. 4,146,542 discloses Carprofen and its pharmaceutically acceptable salt formed with the following pharmaceutically acceptable bases - sodium hydroxide, potassium hydroxide, calcium hydroxide, barium hydroxide, sodium etholate, potassium etholate, piperidine, diethanolamine, N-methylglucamine. It also demonstrates anti-inflammatory, analgesic and anti-rheumatic properties of Carprofen. Further, specification exemplified Carprofen comprising Suppository, Tablet, Capsule and injection formulations.
  • U.S. Patent No. 4,882,164 discloses conventional injection formulations with PEG, Diethanolamine, EDTA sodium salt, benzoyl alcohol and water for injection and injection formulation formed by micelle solution comprising Carprofen or a salt thereof, especially the arginine or lysine salt.
  • European patent No. 0672422 discloses transdermal gel formulations comprising nonsteroidal anti-inflammatory drug of propionic acid derivatives, which includes Carprofen for antiinflammatory and analgesic activity.
  • compositions comprise effective amount of carprofen, one or more polyols, one or more stabilizing agents and optionally, one or more co-solvents. Further, this application teaches the need of stabilizing agents in ensuring stable carprofen formulations that do not degrade.
  • U.S. patent publication No. 20080306132 discloses semi solid compositions comprising Carprofen for veterinary application.
  • Semisolid composition was referred to cream, paste, gel, ointment or jelly.
  • composition comprises water; one or more cosolvents; one or more hydrophilic gelling polymers were disclosed. It is discloses that the oral paste formulation shows improved animal compliance.
  • the drawback of oral semi solid composition is it requires a calibrated syringe for administrating and also causes difficulty for the pet assistant to keep a syringe in the oral cavity and release the semi solid composition.
  • the calibrated syringe can cause damage to the oral cavity of the animal.
  • WO2016073347 publication discloses and refers a stable, palatable, soft chewable oral composition for increased acceptance of the medication in animals, which show resist swallowing hard tablets or capsules and chewing bitter and/or granular dosage forms.
  • Soft chew is referred to a ductile composition, where it is a supple, pliable, flexible form, i.e., is not a brittle form.
  • Specification discloses suitable non-limiting excipients of binding agent, disintegrant, wetting agent, flavorant (meat or vegetables), filler, antioxidant, colorant and taste masking agent. The flavorant is used as an admixture with filler.
  • the soft chewables are prepared by extrusion technique, where above excipients were extruded to a desired shape on a die and cut into individual units for administration. It also exemplified a soft palatable chewable composition comprising NSAID like carprofen, Microcrystalline cellulose (binding agent), disintegrant, glycerol (wetting agent), flavorant/filler and Polyvinylpyrrolidone (taste masking agent).
  • Self-micro emulsifying oral quick-dissolving films for animals which comprises self-microemulsifying component, film- forming material, plasticizer, disintegrant, thickener, and flavouring agent.
  • Self-micro emulsifying components are composed of an oil phase, an emulsifier and a co-emulsifier; the oil phase can be castor oil, olive oil, oleic acid, ethyl oleate, medium chain triglycerides, a mixture of one, two or more of glyceryl oleate and isopropyl myristate; the emulsifier can be selected from polyethylene glycol glycerides, polysorbates, and polyoxyethylene castor oils.
  • the co- emulsifier can be one, two or more mixtures of ethanol, propylene glycol, glycerin, polyethylene glycol, and diethylene glycol monoethyl ether.
  • WO2020172232A1 patent publication discloses and refers a stable, palatable, soft chewable oral composition for increased acceptance of the medication in animals, which show resist swallowing hard tablets or capsules and chewing bitter and/or granular dosage forms.
  • Specification discloses suitable non-limiting excipients of an animal based palatant, a nonanimal based palatant, a flavour modifier, and at least one veterinary acceptable excipient that is selected from at least one each of a disintegrant, binder, lubricant, humectant, and glidant; and the soft chewable tablet is compressed with a rotary tablet press.
  • U.S. patent publication No. 20050136096 discloses edible films for administration of medicaments to animals, wherein the edible film disclosed has an applied coating and a thin film.
  • the applied coating is a powder matrix including one or more medicaments optionally with a carrier is applied as a coating by Sifting, Screening, atomization, Static, mechanical agitation or fluidization etc.
  • the disclosure does not exemplify any Non-steroidal anti-inflammatory drugs, such edible films are limited by animal’s oral mucosa is being directly exposed to the drugs applied over the film, that may be cause sense of irritability or drooling when administered, resulting in dosing error and reluctance to take such films from next dose onwards.
  • the coated medicament on the thin film may be eroded during the process of administration i.e., while taking out from the package and handling it while administering to the animal.
  • Non-steroidal antiinflammatory drugs NSAIDs
  • NSAIDs Non-steroidal antiinflammatory drugs
  • their pharmaceutically acceptable salts thereof include vascular injections, muscular injections and oral administration of liquids or tablets or pills or suspension or spray dosage form or oral paste or soft chewables or drug coated thin films.
  • Disadvantages of these known pharmaceutical delivery methods include difficulty swallowing, difficulty in administration, inconvenience to pet medical staff and pet owners, pain to the animals or pets, cause damage to oral cavity or oesophagus with auxiliary feeders, erosion of drug coated on thin films and difficulty in measuring the dosages when liquids or tablets or pills are added to animal feed, since, for example some time a number of animals or pets will share a common feed container and animals will sometimes try to spit out the medicament which reduces therapeutic effect in the target animals.
  • Parenteral dosage forms are difficult in administration, also cause pain to the animals, maximum attention while administering and pose a danger of self-administering or injury to the administrating volunteer like pet nursing staff during the process of injecting. Moreover, the administration is a like an operative procedure, which requires medical attendant and accompanying staff. Thus, there is need for an effective, pliable, easily administrable dosage form for the pet owner or any volunteer with required minimal attention.
  • NSAIDs Non-steroidal anti-inflammatory drugs
  • the major advantages of this novel oral film dosage form includes reduced or no difficulty while swallowing, avoid scratches and bites during administration, ease of administration, quick disintegration in the oral cavity besides they are less prone to being spit by the animals.
  • the present invention provides oral film of Non-steroidal antiinflammatory drugs (NSAIDs) and its pharmaceutically acceptable salts thereof for veterinary use.
  • NSAIDs Non-steroidal antiinflammatory drugs
  • the present invention provides compositions of oral film of Nonsteroidal anti-inflammatory drugs (NSAIDs) and its pharmaceutically acceptable salts thereof for veterinary use, wherein the composition comprises at least one film forming polymer, plasticizer and one or more pharmaceutically acceptable excipients thereof.
  • NSAIDs Nonsteroidal anti-inflammatory drugs
  • the present invention provides process for preparing oral film of Non-steroidal anti-inflammatory drugs (NSAIDs) and its pharmaceutically acceptable salts thereof for veterinary use, wherein the process may be selected from solvent casting, hot melt extrusion or printing technology.
  • the present invention provides oral film of Non-steroidal antiinflammatory drugs (NSAIDs) and its pharmaceutically acceptable salts thereof used for the treatment or prevention of pain and inflammation in animals.
  • NSAIDs Non-steroidal anti-inflammatory drugs
  • references in the specification to “one embodiment,” “an embodiment,” “another embodiment,” “a preferred embodiment,” “one aspect,” “another aspect,” “preferred aspect” and the like, indicate that the embodiment described can include a particular feature, structure, or characteristic, but every embodiment may not necessarily include the particular feature, structure, or characteristic. Moreover, such phrases are not necessarily referring to the same embodiment. Further, when a particular feature, structure, or characteristic is described in connection with an embodiment, it is submitted that it is within the knowledge of one of ordinary skill in the art to affect such feature, structure, or characteristic in connection with other embodiments whether or not explicitly described.
  • Films are classified by the site of application. Accordingly, “Oral films” can be formulated to deliver medication to the mouth such as oral hygiene products or to deliver medication to the gastrointestinal tract for absorption. “Buccal films” and “sublingual films” are formulated to facilitate absorption through the proximal mucosal membranes avoiding first pass metabolism or degradation in the gastrointestinal tract and providing a quick onset of action.
  • Oral film according to the present invention may also referred as “Oral thin film,” “OTF,” “ODF,” “oral drug strip”, “oral strip”, “veterinary oral film”, “oral disintegrating film” or “oral dissolving film”.
  • veterinary use includes prevention or treatment of veterinary medical conditions in any animal other than human for which oral films of the present invention find useful.
  • Animals herein unless otherwise specified does not limit to only domestic animals such as cats, dogs, guinea pigs, mice, horses, goats, rabbits, swine, apes, primates, hamsters, ferrets, reptiles, sheep, cows, and other animals for which oral films of the present invention find useful.
  • the oral film, according to the present invention preferably disintegrates within about five minutes and more preferably within about 180 seconds upon contact with aqueous media or saliva in oral cavity of the animal.
  • an oral film according to the present invention is "non-mucoadhesive" in nature, means that the dosage form is not designed for administration of the active pharmaceutical agent through the oral mucosa i.e. the dosage form is not designed to adhere to the mucosal surfaces of the buccal cavity as an intact film or disintegrated film residue.
  • the invention provides a non-mucoadhesive orally disintegrating film, able to disintegrate upon contact with aqueous media or saliva in oral cavity of the animal within about five minutes and more preferably within about 180 seconds.
  • film includes films, sheets and wafers, in any size and shape, including rectangular, square, or other desired shape. Preferably, they are distinct from pills, tablets, caplets or capsules and wherein the dosage from is like a thin strip of material.
  • the films are generally sufficiently flexible to allow bending or even folding without breaking.
  • the films described herein may be any desired thickness and size such that it may be placed into the oral cavity of the animal.
  • the films may have a thickness of from about 20 microns to about 300 microns. Films may be in a single layer or they may be multilayered, such as laminated or co-extruded films.
  • disintegrating is defined as a state in which any residue of the oral film remaining on the screen of the test apparatus known in the art, or in the mouth of animal, is a soft mass having no palpably film core.
  • the disintegration test does not imply complete solution of dosage unit or even of its active constituent, although a dissolved dosage unit would typically be completely disintegrated.
  • dissolution is defined by the amount of active agent released from the oral film after oral administration or by in-vitro testing known in the art.
  • An in-vitro dissolution test is to evaluate the performance of the product by measuring the amount of active agent dissolved in the dissolution medium.
  • Standardized apparatus known in the art for in-vitro dissolution testing are: USP type I apparatus (basket), USP type II apparatus (Paddle), USP type V apparatus (Paddle over disk).
  • the present invention is an oral film of Non-steroidal anti-inflammatory drugs (NSAIDs) and its pharmaceutically acceptable salt thereof for veterinary use.
  • the present invention provides composition and process for preparing oral film of Non-steroidal anti-inflammatory drugs (NSAIDs) and its pharmaceutically acceptable salt thereof for veterinary use.
  • Non-steroidal anti-inflammatory drugs are selected from the group comprising of Carprofen, Deracoxib, Etodolac, Firocoxib, Meloxicam, Robenacoxib, Grapiprant and combinations thereof and its pharmaceutically acceptable salts thereof.
  • Non-steroidal anti-inflammatory drugs are selected from hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethane sulfonate, benzenesulfonate, p-toluenesulfonate and pamoate.
  • NSAIDs Non-steroidal anti-inflammatory drugs
  • Non-steroidal anti-inflammatory drugs and its pharmaceutically acceptable salts thereof according to the present invention are may be present in an amount of about 0.1% to about 75% by weight based on total weight of the composition.
  • the present invention provides composition of oral film of Nonsteroidal anti-inflammatory drugs (NSAIDs) and its pharmaceutically acceptable salt thereof, wherein the composition comprises at least one film forming polymer, plasticizer and one or more pharmaceutically acceptable excipients.
  • NSAIDs Nonsteroidal anti-inflammatory drugs
  • one or more pharmaceutically acceptable excipients are selected from the group comprising of suspending/thickening agents, fillers/bulking agents, disintegrating agents, stabilizers, surfactants, sweetening agents, taste masking agents, antifoaming agents, flavoring agents and coloring agents and combinations thereof.
  • the present invention provides oral film of Non-steroidal anti-inflammatory drugs (NSAIDs) and its pharmaceutically acceptable salts thereof comprises one or more Film forming polymers.
  • NSAIDs Non-steroidal anti-inflammatory drugs
  • Film forming polymers are responsible for imparting adequate mechanical properties to films, and they affect the film disintegration and/or dissolution in oral cavity.
  • Film forming polymers used according to the present invention are not limited to hydrophilic or hydrophobic polymers.
  • Suitable non-limiting hydrophilic film forming polymers are selected from hydroxypropyl methylcellulose or Hypromellose, hydroxyethyl cellulose, hydroxypropyl cellulose, sodium carboxy methylcellulose, methyl cellulose, Hydroxypropyl ethylcellulose, polyvinyl pyrrolidone or povidone, copovidone, polydextrose, polyvinyl alcohol, polyvinyl acetate, polyethylene oxide, pullulan, sodium alginate, propylene glycol alginate, modified starch, gelatin, pectin, polyoxyethylene stearates, poly-epsilon caprolactone, polyglycolized glycerides, cyclodextrins, galactomannans, Polymerized rosin and combinations thereof.
  • Suitable non-limiting hydrophobic film forming polymers according to the present invention are selected from ethyl cellulose, Polymethacrylates, polyacrylic acid, methyl methacrylate copolymer, copolymers of acrylic acid and alkyl acrylate, carboxyvinyl copolymers, and combinations thereof.
  • Polymers used according to present invention are available in various viscosity ranges. Depending on the viscosity the quantity of the polymer is chosen.
  • Film forming polymer/s according to the present invention may be present in an amount of about 10% to about 75% by weight based on total weight of the composition.
  • the present invention provides oral film of Non-steroidal anti-inflammatory drugs (NSAIDs) and its pharmaceutically acceptable salts thereof comprises plasticizers.
  • NSAIDs Non-steroidal anti-inflammatory drugs
  • plasticizers are responsible for mechanical properties of the film, such as tensile strength and decrease the fragility of film by decreasing the glass transition temperature of polymer.
  • Suitable non-limiting plasticizers according to the present invention are selected from polyethylene glycol, propylene glycol, polyethylenepropylene glycol, glycerol/glycerin, glycerol monoacetate, glycerol diacetate, glycerol triacetate, triacetin, polysorbate, cetyl alcohol, sorbitol, sodium diethylsulfosuccinate, triethyl citrate, tributyl citrate, dimethyl phthalate, diethyl phthalate, dibutyl phthalate and combinations thereof.
  • Plasticizers according to the present invention may be present in an amount of about 1% to about 30% by weight based on total weight of the composition.
  • Suspending/thickening agents according to the present invention are responsible for improving the viscosity of the drug and excipient dispersion preparation and consistency of the oral film.
  • Suitable non-limiting suspending/thickening agents according to the present invention are selected from maltodextrin, natural gums like xanthan gum, carrageen, locust bean gum, cellulose derivatives, dextrin, modified starch and combinations thereof.
  • Suspending/thickening agents according to the present invention may be present in an amount of about 1% to about 50% by weight based on total weight of the composition.
  • Suitable non-limiting filler/bulking agents are selected from Starches, anhydrous lactose, mannitol, Maltodextrin, dicalcium phosphate, calcium sulfate, cellulose, kaolin, sodium chloride, sorbitol, sucrose and combinations thereof.
  • Disintegrating agents according to the present invention are responsible for quick disintegration of oral film upon contact with aqueous media or saliva in oral cavity.
  • Suitable non-limiting Disintegrating agents according to the present invention are selected from Starch, Colloidal silicon dioxide, microcrystalline cellulose, Crospovidone, Sodium Starch glycolate, Croscarmellose sodium, and combinations thereof.
  • “Sweetening agent or Sweetener” enhances the palatable/taste and pleasurable factor, which makes the film relatively acceptable or agreeable to the patient.
  • suitable non-limiting sweeteners according to the present invention are selected from glucose (com syrup), dextrose, invert sugar, fructose, and combinations thereof; saccharin and its various salts such as the sodium salt; dipeptide sweeteners such as aspartame; dihydrochalcone compounds, glycyrrhizin; Ammonium Glycyrrhizinate, Stevia Rebaudiana (Stevioside), chloro derivatives of sucrose such as sucralose, sugar alcohols such as sorbitol, mannitol, maltodextrin, xylitol, and the like, hydrogenated starch hydrolysates and the synthetic sweetener 3,6-dihydro-6-methyl-l-l-l,2,3-oxathiazin-4-one-2,2-dioxide,
  • taste masking agents are responsible for blocking or diminishing the bitter taste of drug substance or excipients present in the film.
  • Suitable nonlimiting taste masking agents according to the present invention are selected from ion exchange resins, cyclodextrins and its derivatives, ready made available mixtures of taste mask enhancers and combinations thereof.
  • Suitable non-limiting buffering agents are selected from sodium carbonate, sodium bicarbonate, Citric Acid, Sodium Citrate, potassium carbonate, potassium bicarbonate, Ammonium Phosphate Dibasic, Sodium Phosphate Dibasic, sodium phosphate tribasic, potassium phosphate dibasic, potassium phosphate tribasic, Borate, calcium carbonate, magnesium carbonate, sodium hydroxide, magnesium hydroxide, potassium hydroxide, aluminium hydroxide and combinations thereof.
  • Stabilizers according to the present invention are responsible for improving the shelf life by preventing the degradation of active agents.
  • Suitable non-limiting stabilizers according to the present invention are selected from Tocopherol, Ascorbic acid, Citric acid, sodium bisulfite, sodium metabisulfite, propyl gallate, Potassium Metabisulfite, butylated hydroxytoluene and butylated hydroxyanisole and combinations thereof.
  • Suitable non-limiting surfactants according to the present invention are selected from cetyl alcohol, sodium lauryl sulfate, Polyoxyl 40 hydrogenated castor oil, Polyoxyl 15 hydroxystearate, Polysorbate 80, Macrogol stearate, Hydrogenated Castor Oil, Spans®, Tweens®, Ethoxylated oils, poloxamers and combinations thereof.
  • Suitable anti-foaming agents according to the present invention are selected from the group comprising of simethicone or dimethicone any agent that removes air bubbles/entrapped air/void from film-forming compositions.
  • “Flavors” in the present invention are responsible for masking the bitter or nauseating taste of incorporated drug.
  • Suitable non-limiting veterinary acceptable flavoring agents according to the present invention are selected from chicken, turkey, beef, pork, lamb, fish, egg, cheese, edible yeast, dairy products which are of either artificially available or naturally available or extracted from meat or organs of animals.
  • Other non-limiting flavoring agents according to the present invention are selected from the group comprising of natural and synthetic flavoring liquids such agents includes volatile oils, synthetic flavor oils, flavoring aromatics, oils, liquids, oleoresins or extracts derived from plants, leaves, flowers, fruits, stems and combinations thereof.
  • a non-limiting representative list of examples includes mint oils, cocoa, pea nuts and citrus oils such as lemon, orange, grape, lime and grapefruit and fruit essences including apple, pear, peach, grape, strawberry, raspberry, cherry, plum, pineapple, apricot or other fruit flavors.
  • aldehydes and esters such as benzaldehyde (cherry, almond), citral i.e., alphacitral (lemon, lime), neral, i.e., beta-citral (lemon, lime), decanal (orange, lemon), aldehyde C-8 (citrus fruits), aldehyde C-9 (citrus fruits), aldehyde C-12 (citrus fruits), tolyl aldehyde (cherry, almond), 2,6-dimethyloctanol (green fruit), and 2-dodecenal (citrus, mandarin) and combinations thereof.
  • aldehydes and esters such as benzaldehyde (cherry, almond), citral i.e., alphacitral (lemon, lime), neral, i.e., beta-citral (lemon, lime), decanal (orange, lemon), aldehyde C-8 (citrus fruits), aldehyde
  • Suitable coloring agents according to the present invention are selected from the group comprising of food, drug and cosmetic colors (FD and C), drug and cosmetic colors (D and C), or external drug and cosmetic colors (Ext. D and C). These colors are dyes, their corresponding lakes, and certain natural and derived colorants. Other non-limiting examples of coloring agents according to present invention are selected from known azo dyes, organic or inorganic pigments, or coloring agents of natural origin and combinations thereof.
  • excipients used in the oral film of the present invention may have one or more functions i.e. an excipient used in oral film of the present invention may have multi-function like starch and modified starch used in the present invention may also act as a bulking agent and/or disintegrating agent; Maltodextrin used in the present invention may act as a sweetener and/or suspending/thickening agent and/or filler/bulking agent; Mannitol used in the present invention may act as sweetener and/or as a filler/bulking agent; cellulose derivatives used in the present invention may act as a film forming polymer and/or suspending/thickening agent.
  • a skilled person should not construe the limit of an excipient stated or illustrated in any aspect or embodiment or an example of oral film in the present invention to a single function.
  • the present invention provides composition of oral film of Non-steroidal anti-inflammatory drugs (NS AID s) and its pharmaceutically acceptable salt thereof for veterinary use, wherein the composition comprises from about 0.1% to about 75% by weight of Non-steroidal anti-inflammatory drug (NSAIDs) and its pharmaceutically acceptable salt thereof.
  • N AID s Non-steroidal anti-inflammatory drugs
  • NSAIDs Non-steroidal anti-inflammatory drug
  • the present invention provides composition of oral film of Nonsteroidal anti-inflammatory drugs (NSAIDs) and its pharmaceutically acceptable salt thereof for veterinary use, wherein the composition comprises: i. from about 0.1% to about 75% by weight of Non-steroidal anti-inflammatory drug (NSAIDs) and its pharmaceutically acceptable salt; ii. from about 10% to about 75% by weight of at least one film forming polymer; iii. from about 1% to about 30% by weight of plasticizer; and iv. one or more pharmaceutically acceptable excipients; wherein the percentage (%) by weight is relative to the total weight of the composition.
  • NSAIDs Non-steroidal anti-inflammatory drugs
  • the composition comprises: i. from about 0.1% to about 75% by weight of Non-steroidal anti-inflammatory drug (NSAIDs) and its pharmaceutically acceptable salt; ii. from about 10% to about 75% by weight of at least one film forming polymer; iii. from about 1% to about 30% by weight of plasticizer; and iv. one or more pharmaceutically acceptable
  • the present invention provides process for preparing oral film of Non-steroidal anti-inflammatory drugs (NSAIDs) and its pharmaceutically acceptable salts thereof for veterinary use, wherein the process may be selected from solvent casting, hot melt extrusion or printing technology.
  • NSAIDs Non-steroidal anti-inflammatory drugs
  • Solvents used according to the present invention in the process for preparing oral film of Non-steroidal anti-inflammatory drugs (NSAIDs) and its pharmaceutically acceptable salts thereof may be selected from water, a polar organic solvent including, but not limited to, ethanol, isopropanol, acetone, methylene chloride, Dichloromethane or any combination thereof.
  • the present invention provides oral film of Carprofen and its pharmaceutically acceptable salt thereof.
  • the present invention provides composition of oral film of Carprofen and its pharmaceutically acceptable salt thereof, wherein the composition comprises at least one film forming polymer, plasticizer and one or more pharmaceutically acceptable excipients.
  • the present invention provides process for preparing oral film of Carprofen and its pharmaceutically acceptable salt thereof, wherein the process may be selected from solvent casting, hot melt extrusion or printing technology.
  • the present invention provides composition of oral film of Carprofen and its pharmaceutically acceptable salt thereof for veterinary use, wherein the composition comprises from about 0.1% to about 75% by weight of Carprofen and its pharmaceutically acceptable salt thereof.
  • the present invention provides composition of oral film of Carprofen and its pharmaceutically acceptable salt thereof, wherein the composition comprises: i. from about 0.1% to about 75% by weight of Carprofen and its pharmaceutically acceptable salt; ii. from about 10% to about 75% by weight of at least one film forming polymer; iii. from about 1% to about 30% by weight of plasticizer; and iv. one or more pharmaceutically acceptable excipients; wherein the percentage (%) by weight is relative to the total weight of the composition.
  • the present invention provides oral film of Robenacoxib and its pharmaceutically acceptable salt thereof.
  • the present invention provides composition of oral film of Robenacoxib and its pharmaceutically acceptable salt thereof, wherein the composition comprises at least one film forming polymer, plasticizer and one or more pharmaceutically acceptable excipients.
  • the present invention provides process for preparing oral film of Robenacoxib and its pharmaceutically acceptable salt thereof, wherein the process may be selected from solvent casting, hot melt extrusion or printing technology.
  • the present invention provides composition of oral film of Robenacoxib and its pharmaceutically acceptable salt thereof for veterinary use, wherein the composition comprises from about 0.1% to about 75% by weight of Robenacoxib and its pharmaceutically acceptable salt thereof.
  • the present invention provides composition of oral film of Robenacoxib and its pharmaceutically acceptable salt thereof, wherein the composition comprises: i. from about 0.1% to about 75% by weight of Robenacoxib and its pharmaceutically acceptable salt; ii. from about 10% to about 75% by weight of at least one film forming polymer; iii. from about 1% to about 30% by weight of plasticizer; and iv. one or more pharmaceutically acceptable excipients; wherein the percentage (%) by weight is relative to the total weight of the composition.
  • the present invention provides oral film of Deracoxib and its pharmaceutically acceptable salt thereof.
  • the present invention provides composition of oral film of Deracoxib and its pharmaceutically acceptable salt thereof, wherein the composition comprises at least one film forming polymer, plasticizer and one or more pharmaceutically acceptable excipients.
  • the present invention provides process for preparing oral film of Deracoxib and its pharmaceutically acceptable salt thereof, wherein the process may be selected from solvent casting, hot melt extrusion or printing technology.
  • the present invention provides composition of oral film of Deracoxib and its pharmaceutically acceptable salt thereof for veterinary use, wherein the composition comprises from about 0.1% to about 75% by weight of Deracoxib and its pharmaceutically acceptable salt thereof.
  • the present invention provides composition of oral film of Deracoxib and its pharmaceutically acceptable salt thereof, wherein the composition comprises: i. from about 0.1% to about 75% by weight of Deracoxib and its pharmaceutically acceptable salt; ii. from about 10% to about 75% by weight of at least one film forming polymer; iii. from about 1% to about 30% by weight of plasticizer; and iv. one or more pharmaceutically acceptable excipients; wherein the percentage (%) by weight is relative to the total weight of the composition.
  • the present invention provides oral films of Non-steroidal antiinflammatory drugs (NSAIDs) and its pharmaceutically acceptable salts thereof, wherein the oral films comprises therapeutically effective amount of Non-steroidal anti-inflammatory drugs (NSAIDs) and its pharmaceutically acceptable salts thereof are used for the treatment or prevention of pain and inflammation in animals.
  • NSAIDs Non-steroidal antiinflammatory drugs
  • the oral films comprises therapeutically effective amount of Non-steroidal anti-inflammatory drugs (NSAIDs) and its pharmaceutically acceptable salts thereof are used for the treatment or prevention of pain and inflammation in animals.
  • the present invention provides oral films of Carprofen and its pharmaceutically acceptable salt thereof, wherein oral film is used for the treatment or prevention of pain and inflammation in animals.
  • the present invention provides oral films of Robenacoxib and its pharmaceutically acceptable salt thereof, wherein oral film is used for the treatment or prevention of pain and inflammation in animals.
  • the present invention provides oral films of Deracoxib and its pharmaceutically acceptable salt thereof, wherein oral film is used for the treatment or prevention of pain and inflammation in animals.
  • step 3 Add Hydroxypropyl methylcellulose to step 2 under stirring and continue stirring till a homogenous dispersion is obtained.
  • step 6 Add Microcrystalline Cellulose to dispersion of step 4 or step 5 under stirring and continue stirring till a homogenous dispersion is obtained.
  • step 7 Add Propylene glycol to dispersion of step 6 under stirring and continue stirring till a homogenous dispersion is obtained.
  • step 8 Add colorant to dispersion of step 7 under stirring and continue stirring till a homogenous dispersion is obtained.
  • step 8 Add flavor to dispersion of step 8 under stirring and continue stirring till a homogenous dispersion is obtained.
  • step 9 Homogenize the dispersion of step 9 using a homogenizer to obtain a homogenous dispersion.
  • step 10/11 is casted using a film casting machine where the dispersion is spreaded on a backing film to form a thin wet film which passed through a drying zone.
  • the dried film is cut into a desired size by using slitter.
  • step 4 Add Deracoxib to the dispersion of step 3 under stirring and continue stirring till a homogenous dispersion is obtained.
  • step 4 optionally add Poloxamer to the dispersion of step 4 under stirring and continue stirring till a homogenous dispersion is obtained.
  • step 6 Add Starch to dispersion of step 4 or step 5 under stirring and continue stirring till a homogenous dispersion is obtained.
  • step 7 Add Propylene glycol to dispersion of step 6 under stirring and continue stirring till a homogenous dispersion is obtained.
  • step 8 Add colorant to dispersion of step 7 under stirring and continue stirring till a homogenous dispersion is obtained.
  • step 8 Add flavor to dispersion of step 8 under stirring and continue stirring till a homogenous dispersion is obtained.
  • step 9 Homogenize the dispersion of step 9 using a homogenizer to obtain a homogenous dispersion.
  • step 10/11 is casted using a film casting machine where the dispersion is spreaded on a backing film to form a thin wet film which passed through a drying zone.
  • the dried film is cut into a desired size by using slitter.
  • step 3 Add Hydroxypropyl methylcellulose to step 2 under stirring and continue stirring till a homogenous dispersion is obtained.
  • step 4 Add Robenacoxib to the dispersion of step 3 under stirring and continue stirring till a homogenous dispersion is obtained.
  • step 5 Optionally add Macrogol sterate to the dispersion of step 4 under stirring and continue stirring till a homogenous dispersion is obtained.
  • step 7 Add Propylene glycol to dispersion of step 6 under stirring and continue stirring till a homogenous dispersion is obtained.
  • step 8 Add colorant to dispersion of step 7 under stirring and continue stirring till a homogenous dispersion is obtained.
  • step 8 Add flavor to dispersion of step 8 under stirring and continue stirring till a homogenous dispersion is obtained.
  • step 9 Homogenize the dispersion of step 9 using a homogenizer to obtain a homogenous dispersion.
  • step 10/11 is casted using a film casting machine where the dispersion is spreaded on a backing film to form a thin wet film which passed through a drying zone.
  • the dried film is cut into a desired size by using slitter.
  • step 3 Added BHA & BHT to step 2 and stirred with a suitable stirrer to get clear solution.
  • step 8 Added Glycerin to step 7 under stirring and continued stirring till a homogenous dispersion is obtained.
  • the suspension was homogenized using a homogenizer to obtain a homogenous dispersion.
  • the dispersion is casted using a film casting machine where the dispersion is spreaded on a backing film to form a thin wet film which passed through a drying zone.
  • the dried film is cut into a desired size by using slitter. 14. Pack the film into suitable pouches/sachets
  • Disintegration study The obtained oral film of Example 4 is tested for disintegration time using static method, wherein the oral film is placed in a petri dish containing water and in a static condition, the time taken for disintegration is observed:
  • Example 4 • Time taken for disintegration - 54 seconds Dissolution study: Also the obtained film of Example 4 is tested for dissolution in USP type 5 (Paddle over Disc) apparatus, 900ml volume, 75rpm using pH 7.2 Phosphate buffer as dissolution medium and the results are given below:
  • the oral film of the present invention has shown more than 95% of drug is released within 10 minutes, which shows faster release of drug.
  • oral films of the present invention formulated according to an embodiment has shown quick disintegration and dissolution of drug, which solves the problems mentioned above like difficulty of administration, swallowing, dosing errors etc in animals.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne de nouvelles formes posologiques orales de médicaments anti-inflammatoires non stéroïdiens (AINS) et de leurs sels pharmaceutiquement acceptables pour une utilisation vétérinaire, par exemple pour une administration orale à des animaux. Plus spécifiquement, la présente invention concerne des compositions et un procédé de préparation d'un film oral comprenant des médicaments anti-inflammatoires non stéroïdiens (AINS) et leurs sels pharmaceutiquement acceptables.
PCT/IN2022/051137 2021-12-30 2022-12-29 Films oraux de médicaments anti-inflammatoires non stéroïdiens WO2023126970A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202141062000 2021-12-30
IN202141062000 2021-12-30

Publications (1)

Publication Number Publication Date
WO2023126970A1 true WO2023126970A1 (fr) 2023-07-06

Family

ID=86998516

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2022/051137 WO2023126970A1 (fr) 2021-12-30 2022-12-29 Films oraux de médicaments anti-inflammatoires non stéroïdiens

Country Status (1)

Country Link
WO (1) WO2023126970A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010006046A1 (fr) * 2008-07-10 2010-01-14 Tyrx Pharma, Inc. Administration de médicaments anti-inflammatoires non stéroïdiens issus de polyarylates
WO2017134418A1 (fr) * 2016-02-02 2017-08-10 Ucl Business Plc Produits et procédés pour administration orale
EP3215120A1 (fr) * 2014-11-03 2017-09-13 Zoetis Services LLC Composition vétérinaire à mâcher appétissante

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010006046A1 (fr) * 2008-07-10 2010-01-14 Tyrx Pharma, Inc. Administration de médicaments anti-inflammatoires non stéroïdiens issus de polyarylates
EP3215120A1 (fr) * 2014-11-03 2017-09-13 Zoetis Services LLC Composition vétérinaire à mâcher appétissante
WO2017134418A1 (fr) * 2016-02-02 2017-08-10 Ucl Business Plc Produits et procédés pour administration orale

Similar Documents

Publication Publication Date Title
US8025897B2 (en) Ibuprofen composition
EP1219291B1 (fr) Particules avec une texture masquée, comprenant un principe actif
CA2690956C (fr) Comprime de combinaison avec une couche exterieure pouvant etre machee
US20160030354A1 (en) Combination tablet with chewable outer layer
US20100086495A1 (en) Compositions and methods for enhancing transmucosal delivery
JP2000508649A (ja) 速崩解性経口剤形物
US20070259040A1 (en) Novel triptan formulations and methods for making them
CN105106178A (zh) 食用膜的制备方法
WO2014024193A1 (fr) Compositions et procédés d'administration rapide, à travers les muqueuses, d'ingrédients pharmaceutiques
US20110086070A1 (en) Orally disintegrating compositions of rhein or diacerein
AU2020303338A1 (en) Transmucosal therapeutic system containing agomelatine
CN105193772A (zh) 一种沙格列汀口腔膜剂及其制备方法
KR20200018652A (ko) 타액에 멜라토닌을 가용화하는 산성화제를 포함하는 구강 용해 멜라토닌 제제
US20220008342A1 (en) Combination tablet with chewable outer layer
US10226450B2 (en) Pharmaceutical film composition
TWI664969B (zh) 格拉匹綸(ｇｒａｐｉｐｒａｎｔ)組合物及其使用方法
WO2023126970A1 (fr) Films oraux de médicaments anti-inflammatoires non stéroïdiens
MX2007009275A (es) Procedimiento de produccion de pastillas que contienen maine, sus composiciones y su uso medicinal.
WO2023126971A1 (fr) Films oraux de médicaments anti-émétiques
WO2023126967A1 (fr) Films oraux de médicaments antiprurigineux
WO2023126969A1 (fr) Films oraux de médicaments anti-parasitaires
JP2023502209A (ja) アピキサバンの口腔内崩壊性医薬組成物
WO2024031193A1 (fr) Formulation de film orale à chargement élevé présentant une biodisponibilité améliorée
CA3211232A1 (fr) Film oral de modulateur(s) du cftr
US20110092602A1 (en) Rapidly disintegrating oral compositions of tramadol

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22915392

Country of ref document: EP

Kind code of ref document: A1